Frazier Life Sciences Acquisition Corp. II (FLSC) reported that Frazier Life Sciences Holdings II LLC purchased 300,000 Class A ordinary shares at $10.00 per share on October 15, 2026; the LLC reported 300,000 shares following the transaction. Albert Cha, listed as Chief Executive Officer, director and 10% owner, is identified as the LLC’s sole manager. Frazier Life Sciences Holdings II LLC, Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P. and FHMLSP, L.L.C. are each listed as 10% owners; the footnote describes the fund and general-partner ownership chain. The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest, if any. No Rule 10b5-1 plan is reported.
Frazier Life Sciences Acquisition Corp. II (FLSC) completed its initial public offering on October 15, 2026, selling 7,500,000 Class A ordinary shares at $10.00 per share for $75,000,000 in gross proceeds. It also completed a private placement of 300,000 Private Placement Shares at $10.00 each, generating $3,000,000 in gross proceeds.
The company placed $75,000,000 of IPO and private-placement proceeds in a U.S.-based trust account for public shareholders. Except for interest released to pay taxes and up to $100,000 of interest for liquidation and dissolution expenses, trust funds are not released to the company until an initial business combination; public shareholders may receive redemptions in specified circumstances. The company must complete a business combination within 24 months from IPO closing, unless an earlier date is approved by its board or a later date is approved by shareholders, subject to applicable law. Private Placement Shares cannot be transferred or sold until 30 days after completion of the business combination unless public shareholders approve otherwise.
Frazier Life Sciences Acquisition Corp. II (FLSC) is offering 7,500,000 Class A ordinary shares for $75,000,000 at $10.00 per share. Underwriting discounts and commissions are $4,500,000, leaving $70,500,000 in proceeds before expenses. The company says $75,000,000 will be placed in a U.S. trust account; IPO investors receive no warrants.
FLSC has not selected a business-combination target and says it intends to focus on biotechnology. It has 24 months from the offering’s closing to complete a transaction, subject to possible amendment. Public shareholders may redeem shares for cash based on trust-account funds, while a shareholder, affiliates and persons acting as a group generally may not redeem more than 15% of the offering’s public shares without company consent. Sponsor Frazier Life Sciences Holdings II LLC agreed to buy 300,000 private-placement shares for $3,000,000 at closing. Separately, Frazier Life Sciences Public Fund, L.P. committed to buy at least 2,500,000 shares for $25,000,000 at $10.00 each, subject to investment committee approval before a definitive business-combination agreement. Including the private placement, initial shareholders will own 2,175,000 shares, or 22.5%, immediately after the IPO; the prospectus identifies immediate material dilution from founder shares.
Frazier Life Sciences Acquisition Corp. II identifies Kevin Li as its Chief Business Officer.
Frazier Life Sciences Acquisition Corp. II (FLSC) reports that Chief Financial Officer Francis Sherman Adams directly holds 14,063 Class B ordinary shares as of October 13, 2026. The shares convert into Class A ordinary shares one-for-one, subject to adjustment, immediately before, concurrently with or immediately after the initial business combination; Adams may elect conversion at any time before it. The shares have no expiration date.
Frazier Life Sciences Acquisition Corp. II director Benjamin L. Palleiko reported direct holdings of 87,188 Class B ordinary shares as of October 13, 2026. GTBAP Limited Partnership holds 30,000 Class B ordinary shares. Palleiko is the sole manager of GTBAP’s general partner, Corrugated Capital LLC, and disclaims beneficial ownership of GTBAP’s shares except to the extent of his pecuniary interest, if any.
The Class B ordinary shares convert into Class A ordinary shares on a one-for-one basis, subject to adjustment. Conversion occurs immediately prior to, concurrently with or immediately following consummation of the issuer’s initial business combination, or earlier at the reporting person’s option. The shares have no expiration date.
Frazier Life Sciences Acquisition Corp. II (FLSC) lists director Richard Scott Struthers as directly holding 30,000 Class B ordinary shares as of October 13, 2026. The shares convert into Class A ordinary shares on a one-for-one basis, subject to adjustment, immediately prior to, concurrently with or immediately following the issuer’s initial business combination, or earlier at his option; they have no expiration date.
Frazier Life Sciences Holdings II, LLC, the sponsor of Frazier Life Sciences Acquisition Corp. II (FLSC), held 1,683,749 Class B ordinary shares as of October 13, 2026. The shares will automatically convert into Class A ordinary shares one-for-one, subject to adjustment, immediately prior to, concurrently with or immediately following consummation of the initial business combination; they may convert earlier at the Reporting Person’s option. Albert Cha, FLSC’s Chief Executive Officer and the sponsor’s sole manager, is a reporting person. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
Frazier Life Sciences Acquisition Corp. II’s Form 3 identifies Alexandra Jackson as a reporting person and lists her role as General Counsel.